Roche Holding AG (RHHBY)
| Market Cap | 253.34B |
| Revenue | 68.00B |
| Net Income | 13.90B |
| Shares Out | 6.45B |
| EPS | 2.03 |
| PE Ratio | 19.34 |
| Forward PE | 12.72 |
| Dividend | $1.39 (3.55%) |
| Ex-Dividend Date | Mar 14, 2024 |
| Volume | 255,700 |
| Open | 39.23 |
| Previous Close | 39.32 |
| Day's Range | 39.11 - 39.36 |
| 52-Week Range | 29.20 - 39.92 |
| Beta | 0.13 |
| Analysts | Hold |
| Price Target | 40.00 (+1.86%) |
| Earnings Date | n/a |
About RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, RHHBY's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 12.36 billion, a decrease of -8.67%.
Financial numbers in CHF Financial StatementsAnalyst Forecast
According to one analyst, the rating for RHHBY stock is "Hold" and the 12-month stock price forecast is $40.0.
News
HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- #Cardiology--HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer.
New data for Roche's Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
Basel, 18 July 2024 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for the ...
New Data for Genentech's Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluati...
Mizuho's Jared Holz talks Roche shares surging on GLP-1 data
Jared Holz, Mizuho, joins 'Fast Money' to talk stock movement in the healthcare space on Roche's oral GLP-1 data.
Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study. The study met al...
Roche's Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study.1 The study met all primary endpoints, showing that Vabysmo® (faricimab) w...
Novo Nordisk, Eli Lilly Slip as Roche Weight-Loss Drug Shows Promise
A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, sending shares of rival GLP-1 developers Eli Lilly and Company (LLY) and N...
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its ex...
Roche shares jump on drugmaker's early-stage data on weight-loss drug
Shares of Swiss drugmaker Roche rallied on Wednesday after the company's early-stage trial of an oral weight-loss drug showed it had promise.
Roche Climbs As Once-Daily Weight Loss Pill Shows Promise
Shares of Swiss pharma giant Roche climbed Wednesday after it reported promising results for an experimental weight loss pill, part of a cohort of hopeful competitors racing to challenge Novo Nordisk ...
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche
Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss ...
Roche reports positive early results in CT-966 obesity drug trial
Roche said on Wednesday that its CT-996, a GLP-1 receptor agonist to treat obesity and type 2 diabetes, has had positive results in phase one of its clinical trial.
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from two arms of an ongoing multi-part Phase...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-dai...
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration
The collaboration leverages Remix's REMaster™ platform to discover novel drugs for a diverse range of target classes Remix is eligible to receive up to $1 billion in milestone payments and royalties W...
W. Robert Berkley and John C. Roche Named Chair and Vice Chair of The Institutes Board of Trustees
MALVERN, Pa.--(BUSINESS WIRE)--The Institutes have appointed W. Robert Berkley Jr. as chair, and John C. (Jack) Roche as vice chair, of the organization's Board of Trustees.
In France, political paralysis is economic paralysis: David Roche
David Roche, strategist at Quantum Strategy, discusses the economic implications of the latest political developments in France.
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. This significant m...
Roche reintroduces recalled eye implant in US
Genentech, a unit of Roche Group , said on Monday it has reintroduced its ocular implant, Susvimo, in the United States, following the end of a voluntary recall.
Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
Basel, 08 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of p...
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for ...
Keir Starmer does not have the tools or vision to turn the UK economy around: David Roche
David Roche of Quantum Strategy says he expects the markets to respond positively to a victory for the Labour Party's Keir Starmer, but this does not change the declining trajectory of the UK economy.
FDA approves Roche's Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
Basel, 05 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6.0 mg single-dose prefilled syri...
FDA Approves Genentech's Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) has approved the Vabysmo® ...
Roche to halt trial in latest setback for lung cancer immunotherapy
Roche will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck & Co , casting further doubt on the drug candidate p...